PT-141 (Bremelanotide) Geriatric (65+) Caregiver Administration Guidance

What Is Bremelanotide and Why Does Age Matter?

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist (MC1R, MC3R, MC4R) that acts centrally to increase sexual desire. The FDA approved Vyleesi on August 21, 2019 for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, based on the RECONNECT phase 3 trials [1]. Unlike phosphodiesterase-5 inhibitors, it does not act peripherally on vascular smooth muscle, but it does produce a transient, clinically meaningful rise in blood pressure in a significant proportion of users.

Patients 65 and older represent a distinct physiological population. Baroreceptor sensitivity declines with age, arterial stiffness rises, and polypharmacy is common, meaning the blood-pressure transient that is an acceptable side effect in a 35-year-old can be hazardous in an 80-year-old on antihypertensives [2]. The RECONNECT trials enrolled primarily premenopausal women, so the geriatric dataset is limited. Prescribers and caregivers must extrapolate from pharmacokinetic sub-studies and general geriatric pharmacology principles.

Pharmacokinetics in Older Adults

Bremelanotide reaches peak plasma concentration (Cmax) approximately 1 hour after subcutaneous injection. Its half-life is roughly 2.7 hours, with renal excretion accounting for the majority of elimination [3]. In adults with severe renal impairment (creatinine clearance <30 mL/min), bremelanotide AUC increases approximately 1.2-fold per FDA labeling, which is not considered clinically significant enough to mandate a dose reduction, but does prolong the period of potential cardiovascular effect [4].

Age-related declines in glomerular filtration rate (GFR) averaging 1 mL/min per year after age 40 mean that a 70-year-old with a serum creatinine of 1.0 mg/dL may have an estimated GFR of 55 to 65 mL/min rather than the 90+ mL/min assumed in younger adults [5]. Caregivers should confirm the prescribing clinician has reviewed current renal function before each course of therapy.

Central Mechanism and Geriatric CNS Considerations

MC4R agonism in the hypothalamus drives the pro-sexual effect of bremelanotide. MC1R activity explains the skin hyperpigmentation (focal, lasting) that occurs in 1 to 2 percent of users, more visible in patients with lighter complexions. In older adults, hypothalamic sensitivity to peptide signals may differ from younger cohorts, though no dedicated geriatric CNS pharmacodynamic studies exist for this compound [6]. Nausea, the most frequent adverse event at 40 percent of users in the RECONNECT trials, may be more severe and prolonged in older adults given slower gastric emptying rates commonly associated with aging.

FDA Labeling and What It Says About Older Patients

The FDA prescribing information for Vyleesi (Revised 2021) states: "Clinical studies of bremelanotide did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects" [4]. This statement carries direct caregiver implications: the safety profile established in key trials does not extend with confidence to geriatric patients, so each administration warrants heightened vigilance.

Cardiovascular Safety Warning

The FDA label includes a boxed-adjacent warning regarding blood pressure. In the RECONNECT studies, 40 percent of bremelanotide-treated patients experienced a mean maximum systolic BP increase of 6 mmHg and a mean maximum diastolic increase of 3 mmHg within 12 hours of dosing [4]. Individual increases exceeded 40 mmHg systolic in some participants.

Blood pressure returns to baseline within 12 hours for most users, but the FDA requires that bremelanotide not be used in patients with uncontrolled hypertension or known cardiovascular disease [4]. For an older patient on three antihypertensive agents with a baseline systolic of 138 mmHg, a 40 mmHg spike could generate a systolic of 178 mmHg, a range associated with acute hypertensive events [7].

Contraindications Relevant to the 65+ Population

The following conditions, more prevalent in patients over 65, are listed as contraindications or strong precautions in FDA labeling [4]:

• Uncontrolled hypertension
• Cardiovascular or cerebrovascular disease
• High cardiovascular risk (defined as 10-year ASCVD risk >10% by ACC/AHA Pooled Cohort Equations)

Caregivers should verify with the prescribing provider that a 10-year ASCVD risk calculation has been documented within the prior 12 months. The ACC/AHA 2019 cardiovascular risk guidelines recommend this calculation for adults aged 40 to 79 [8].

Caregiver Preparation Before the First Injection

Confirm Medical Clearance

Before handling the auto-injector for the first time, the caregiver should confirm three items in writing from the prescribing clinician:

1. Current blood pressure is controlled (systolic <130 mmHg per 2017 ACC/AHA hypertension guidelines [7]).
2. Estimated GFR has been reviewed in the past 6 months.
3. A current medication reconciliation has been completed, specifically checking for medications that may interact with bremelanotide.

The FDA label identifies no major CYP-based drug interactions, but naltrexone and indomethacin attenuate bremelanotide's pharmacodynamic effect [4]. More relevant to geriatric patients is the additive hypotensive potential of antihypertensives when combined with the post-dose vasodilation that can follow the initial BP spike.

Obtain a Baseline Blood Pressure

Measure the patient's blood pressure at rest 15 minutes before injection. Document this number. The American Heart Association's 2017 guideline defines normal as <120/80 mmHg and hypertension stage 1 as 130 to 139/80 to 89 mmHg [7]. If the pre-dose systolic reads 140 mmHg or higher, do not administer the dose. Contact the prescribing clinician instead.

A validated automated upper-arm cuff is preferred over a wrist device in older adults, as peripheral artery stiffness reduces wrist-cuff accuracy [9]. The caregiver should record date, time, and the exact reading in a log the prescribing team can review.

Review the Auto-Injector Device

Vyleesi is supplied as a single-use, prefilled auto-injector containing 1.75 mg bremelanotide in 0.4 mL solution. Each device is intended for a single injection only. Key handling steps before administration [4]:

• Inspect the solution through the viewing window. It should be clear and colorless to pale yellow. Do not use if particulate matter or discoloration is present.
• Allow the device to reach room temperature for 30 minutes if refrigerated. Cold injection increases discomfort and may alter absorption rate.
• Remove the cap only immediately before injection. Once the cap is removed, the device cannot be re-capped safely.

Injection Technique for Geriatric Patients

Site Selection and Rotation

The FDA-approved injection sites are the abdomen (at least 2 inches from the navel) and the outer thigh. In patients over 65, subcutaneous fat distribution shifts, with less abdominal subcutaneous tissue in some older men and redistribution to central depots in postmenopausal women [10]. The caregiver should assess tissue depth visually. A pinch technique, lifting a fold of skin between thumb and forefinger, helps ensure the needle enters subcutaneous rather than intradermal tissue.

Rotate sites with each injection to minimize the risk of lipodystrophy, a concern amplified in older adults who may have reduced skin turgor and slower tissue recovery [10].

Step-by-Step Injection Procedure

1. Wash hands thoroughly with soap and water for at least 20 seconds (CDC hand hygiene standard [11]).
2. Position the patient either sitting upright or lying down. Avoid the standing position in older adults because the post-injection BP change combined with orthostatic hypotension common in this age group could precipitate a fall.
3. Clean the selected site with an alcohol swab and allow it to air-dry for 10 seconds.
4. Pinch the skin firmly, press the auto-injector flat against the skin at a 90-degree angle, and activate the device according to manufacturer instructions.
5. Hold the device in place for 10 seconds after activation to allow full dose delivery.
6. Dispose of the used auto-injector immediately in an approved sharps container. Do not recap or reuse.

Needle Depth and Geriatric Skin

The Vyleesi auto-injector uses a fixed-depth needle. Clinical pharmacokinetic studies showed comparable systemic exposure across BMI ranges of 18 to 45 kg/m2, suggesting the fixed depth is sufficient across most adult body habitus types [4]. Patients with BMI <18.5 kg/m2, a category including some older adults with malnutrition or sarcopenia, should have needle depth discussed with the prescribing clinician before first injection, as very thin subcutaneous layers can result in inadvertent intramuscular injection.

Post-Injection Monitoring Protocol for Caregivers

Blood Pressure Monitoring Timeline

Given the 12-hour window of potential BP elevation, the caregiver should measure blood pressure at 30 minutes, 60 minutes, and 2 hours post-injection. If a reading at any time point exceeds 160/100 mmHg (hypertension stage 2 per ACC/AHA [7]), the following steps apply:

1. Have the patient lie down in a comfortable position.
2. Do not administer any additional medications without clinician guidance.
3. Re-measure BP every 10 minutes.
4. If BP remains above 160/100 mmHg after 20 minutes or the patient develops headache, chest discomfort, visual changes, or confusion, call emergency services immediately.

The 2023 European Society of Hypertension guidelines similarly recommend emergency evaluation for acute systolic readings above 180 mmHg [12].

Nausea Management

Nausea occurred in 40.1 percent of bremelanotide-treated participants in RECONNECT versus 8.7 percent for placebo [1]. In a geriatric patient, prolonged nausea can lead to dehydration, reduced oral medication absorption, and orthostatic hypotension. The caregiver should ensure the patient has eaten a light meal 1 to 2 hours before injection, remains seated or reclined for at least 60 minutes afterward, and has access to oral hydration.

The prescribing clinician may pre-authorize a 4 mg ondansetron orally 30 minutes before injection as prophylaxis. Ensure the medication reconciliation confirms no QT-prolonging interactions, as older adults are more susceptible to drug-induced QT prolongation [13].

Monitoring for Skin Hyperpigmentation

Focal hyperpigmentation, most commonly affecting the face, breasts, and gingiva, occurred in 1 percent of RECONNECT participants [1]. In patients with darker skin tones, this may be less noticeable but can still be present. Caregivers should examine the injection site and face at each administration. Any new pigmented lesions should be documented and reported to the prescribing clinician before the next dose is given.

Fall Risk and Mobility Considerations

Bremelanotide's BP transient, combined with the orthostatic hypotension that affects roughly 20 percent of adults over 65, creates a meaningful fall risk window [14]. The caregiver should enforce a 60-minute seated or supine rest period after injection. Ambulation assistance should be available if the patient needs to use the bathroom during this window.

For patients currently prescribed alpha-blockers (e.g., tamsulosin, doxazosin), ACE inhibitors, ARBs, or diuretics, the additive hypotensive effect may be more pronounced after the initial BP peak subsides. A conversation with the prescribing clinician about timing of daily antihypertensive doses on injection days is appropriate [7].

The HealthRX Geriatric Bremelanotide Administration Framework (GAF-1) organizes caregiver tasks into three phases: Pre-Dose (BP check, GFR verification, medication reconciliation), Active Dose (positioning, injection technique, sharps disposal), and Post-Dose (BP monitoring at 30, 60, and 120 minutes, nausea management, fall prevention for 60 minutes). Clinicians can use this framework as a checklist during caregiver training visits.

Drug Interactions Particularly Relevant to Older Adults

Polypharmacy affects more than 40 percent of adults aged 65 and older, with many patients taking five or more prescription medications concurrently [15]. The FDA label for bremelanotide identifies two specific pharmacodynamic interactions:

• Naltrexone: Reduces bremelanotide efficacy by blocking MC receptor downstream signaling. Older adults prescribed low-dose naltrexone for pain or fibromyalgia should have this conflict resolved before starting bremelanotide [4].
• Indomethacin: Reduces efficacy through prostaglandin pathway interference. NSAIDs are frequently prescribed in older adults for musculoskeletal pain and should be flagged during medication reconciliation [4].

Beta-blockers do not formally interact with bremelanotide pharmacokinetically, but they blunt the reflex tachycardia that normally counteracts a hypotensive rebound, which could worsen orthostatic symptoms in the 2-hour post-dose window [16].

Communicating With the Prescribing Team

Caregivers should keep a standardized log for each administration that records the following: date and time of injection, injection site used, pre-dose BP, post-dose BP at 30, 60, and 120 minutes, any nausea severity on a 0 to 10 scale, and any other adverse events observed. This log should be uploaded to the patient's telehealth portal or faxed to the prescribing clinician within 24 hours of each administration.

If the patient reports persistent nausea beyond 4 hours, headache rated above 6 out of 10, or any visual changes, the caregiver should contact the provider the same day. Emergency services should be contacted immediately for chest pain, loss of consciousness, slurred speech, or sudden severe headache [4].

The FDA MedWatch program (1-800-FDA-1088) is available for caregivers to report serious adverse events directly if the prescribing clinician is unavailable [4].

Dosing Schedule and Frequency Limits

Bremelanotide may not be used more than once in any 24-hour period. The FDA label caps use at no more than 8 doses per month based on the frequency studied in the RECONNECT trials [4]. Exceeding this frequency has not been studied for long-term safety, and cumulative BP exposure effects in older adults are unknown.

The 45-minute pre-activity onset window should be discussed with patients and caregivers so timing expectations are set correctly. Injecting too far in advance, beyond 90 minutes before activity, may result in peak plasma levels having already declined substantially given the 2.7-hour half-life [3].

For patients who miss a planned dose window, the dose should simply be skipped. There is no dose-doubling protocol and no clinical basis for administering a late dose after the activity window has passed.

Training Resources and Caregiver Competency

The prescribing clinician or their clinical staff should provide hands-on injection training before a caregiver administers bremelanotide independently. Training should include a return demonstration on an injection pad. Written materials provided by the manufacturer (AMAG Pharmaceuticals, now acquired by Covis Pharma) include a patient and caregiver instruction booklet available through the Vyleesi support line.

Caregiver competency should be documented in the medical record. For older patients in assisted living or skilled nursing facilities, facility nursing staff may need to be the designated administrator, which requires formal medication administration training consistent with state nursing board requirements [17].

The Institute for Safe Medication Practices (ISMP) identifies injectable drugs as a high-alert medication category requiring independent double-checks in institutional settings [18]. Even in home settings, a second verification step, such as the caregiver reading the lot number and expiration date aloud to the patient before injection, reduces preparation errors.